7 Best Peptides for Spinal Cord Injury

What to Know Before Choosing a Peptide for Spinal Cord Injury

Spinal cord injury sits at one of the most difficult frontiers in medicine. Three overlapping biological barriers make natural recovery rare: physical scarring at the injury site, chemical signals in that scar tissue that actively block nerve fiber regrowth, and post-traumatic inflammation that continues damaging surviving tissue long after the initial event. The compounds in this guide each target one or more of those barriers, but their evidence bases sit at very different points on the spectrum from preclinical animal models to completed human trials.

A compound earns a slot in this guide because people use it or are actively discussing using it for spinal cord injury recovery. That is the whole inclusion test. FDA-approved, telemedicine-prescribed, and research-only compounds are all eligible. A compound with only community-reported use still belongs here, with its thin evidence stated plainly rather than used as a filter. Spinal cord injury is a context where the gap between what has been formally validated and what people are actually trying is unusually large, and pretending otherwise by listing only the well-studied options would make this guide genuinely less useful.

These compounds are numbered by how prominently each appears in the research and in documented real-world use, not as a recommendation of one over another. Number one is not the best compound for everyone. It is the one that has traveled furthest in terms of human evidence and community attention as of mid-2026. The right compound for any individual depends on the nature and completeness of the injury, how far out from the injury they are, and what they build in conversation with the app and, ideally, with a specialist who knows the SCI field. The order is a spine for the list. It is not a verdict.

1. NVG-291: The Only Peptide in Human SCI Trials

NVG-291 is the human clinical analog of a compound called ISP (intracellular sigma peptide), originally developed at Case Western Reserve University's Silver Lab. It is the only peptide that has completed human clinical trials specifically for spinal cord injury, and as of mid-2026 it stands in a different category from every other compound on this list.

To understand why it works, you need to understand what it is working against. When the spinal cord is injured, the body forms a glial scar at the injury site. That scar contains proteins called chondroitin sulfate proteoglycans, which researchers have described as a sticky chemical quagmire that traps the tips of growing nerve fibers. These proteins work by activating a receptor on neurons called PTPsigma, which essentially switches off the neuron's ability to extend and grow. NVG-291 blocks that PTPsigma receptor, flipping the switch back on and allowing nerve fibers to push through the scar rather than being stopped at its edge. It does not dissolve or remove the scar. It lets nerves grow through it.

What makes this peptide practically significant is its delivery mechanism. NVG-291 incorporates a TAT shuttle sequence, a molecular tag that allows it to penetrate cell membranes and the dense glial scar without being injected directly into the spinal cord. That means it can be administered as a systemic injection anywhere in the body and still reach the injury site, which is a meaningful advantage for a treatment targeting tissue as delicate as the spinal cord.

The clinical evidence is the strongest in the SCI peptide field, though still early. A Phase I safety trial confirmed tolerability with no serious adverse events. The Phase Ib/IIa CONNECT SCI study, completed in late 2025 and early 2026, enrolled 10 participants with chronic incomplete cervical spinal cord injuries who had been injured between one and ten years earlier. Over a 12-week treatment course, participants showed a 3.7-point improvement on the GRASSP scale, a standardized measure of hand grasping ability, along with improved electrical impulses in the limbs and restored signaling between the brain and hand muscles. One participant described progressing from being unable to walk to covering short distances unaided. Perhaps the most striking finding was that participants reported these gains persisting one year after stopping the drug. NervGen, the company developing it, characterized the results as demonstrating unprecedented durable improvement in function, independence, and quality of life, language that reflects what the blinded exit interviews showed.

NVG-291 is not commercially available. Access requires enrolling in a clinical trial. As of mid-2026, NervGen is actively preparing for Phase III. The FDA has granted both Fast Track and Orphan Drug designations, and in September 2024 the FDA confirmed that multiple regulatory pathways exist to support its potential approval as the first pharmacologic treatment for spinal cord injury. The Shirley Ryan AbilityLab is a key research site. For those with chronic incomplete cervical injuries who qualify, clinical trial enrollment is the current route to access.

In the preclinical record behind this compound, more than 80 percent of rats in ISP studies regained muscle function, with restored limb, bladder, and diaphragm function. Those results drove the human trial program, and the human data, while still small in sample size, is showing a direction consistent with that earlier animal work.

2. BPC-157: For Vascular Repair and Secondary Neuroprotection

BPC-157, short for Body Protection Compound-157, is a synthetic peptide derived from a protein found in gastric juice. It has one of the broadest preclinical records in the peptide research space and is used extensively in the self-experimentation community across a range of recovery goals. In the context of spinal cord injury, people reach for it primarily for its vascular repair and anti-inflammatory properties.

The core mechanism relevant to SCI is angiogenesis, the formation of new blood vessels in damaged tissue. BPC-157 promotes this process, which helps restore blood supply disrupted by the injury. Reduced blood flow after spinal cord injury contributes to what researchers call secondary injury, the wave of additional tissue death that occurs in the hours and days following the initial trauma. Animal studies have shown BPC-157 reducing perilesional tissue loss, meaning it limits the spread of damage outward from the primary injury site, and improving hindlimb locomotion in rodent SCI models. There is also some preclinical evidence suggesting it may support axon regeneration in both spinal cord and peripheral nerve injury contexts.

The honest state of the evidence is that no randomized controlled trial has been published for BPC-157 in humans with spinal cord injury. The scientific literature for this specific application is animal-only as of mid-2026. The community-reported experiences are real but confounded. Several people in the SCI community report using BPC-157 and noticing improvements in sensation, motor function, and bladder awareness in the weeks following use, though they consistently acknowledge uncertainty about causation given concurrent physical therapy and natural recovery timelines. One community member with a C7 injury described regaining toe movement and bladder sensation after a month of use, while another used a combination including BPC-157 alongside other compounds and reported being able to flex the left knee and walk with orthotics. These accounts surface regularly enough in SCI forums that dismissing them outright would misrepresent the community conversation, but they cannot substitute for controlled data.

BPC-157 is available as a research chemical from unregulated online vendors, without FDA approval for any human use. Quality and purity in products from this market are unverified. There is no validated dosing protocol for spinal cord injury. This compound is used because the animal data is promising and because it is accessible in a context where the alternatives are either a clinical trial or nothing, but the evidence base for the SCI application specifically is preclinical only.

3. TB-500: For Remyelination and Neurogenesis

TB-500 is a synthetic version of a fragment of Thymosin Beta-4, a naturally occurring protein involved in cell repair and regulation across multiple tissue types. In the SCI community, TB-500 is often used alongside BPC-157, and its appeal in this context comes from a somewhat different set of mechanisms: its studied effects on neurogenesis, remyelination, and neuroinflammation.

Remyelination refers to the restoration of the myelin sheath, the insulating layer around nerve fibers that allows electrical signals to travel quickly and reliably. Spinal cord injury damages or destroys myelin along affected nerve pathways. Thymosin Beta-4 has shown activity in animal models of brain injury and stroke related to promoting new neuron formation and supporting myelin restoration, and those mechanisms translate conceptually to spinal cord injury even though the specific evidence base is from related rather than identical models. TB-500 also attenuates post-injury neuroinflammation, one of the ongoing sources of secondary damage after acute SCI.

No human clinical trial data exists for TB-500 in spinal cord injury as of 2026. Thymosin Beta-4 has been studied in human trials for other indications including wound healing and cardiac injury, which establishes some safety context, but none of that data transfers directly to SCI outcomes. What exists in the SCI space is user-reported experience, most of it from people using TB-500 as part of a broader protocol alongside BPC-157, physical therapy, and other interventions. Community reports describe gradual functional improvements over months of use, though the same causation uncertainty that applies to BPC-157 applies equally here. Separating TB-500's contribution from everything else in a multi-month recovery context is not something anecdotal reporting can accomplish.

TB-500 is available from the same research chemical market as BPC-157, with the same caveats about purity, dosing, and the absence of validated protocols. The evidence here is experiential rather than clinical, and anyone considering it should understand that the SCI application is built on extrapolation from related animal models and community observation.

4. VD11: A Preclinical Standout for Scar Reduction

VD11 is an amphibian-derived neuroprotective peptide that has attracted attention in preclinical SCI research for its results in rat models, particularly its effects on glial scar reduction and motor function recovery. It has not been used in humans and has no clinical trial data. It belongs in this discussion because researchers are actively studying it and its results in animal models are strong enough to have generated genuine interest in the SCI research community.

In rat models of spinal cord injury, VD11 showed strong structural and functional recovery outcomes. The most striking finding was its effect on glial scarring: VD11 produced three times greater reduction in glial scar compared to another compound studied in the same model. Enhanced axon growth and motor function recovery were both observed. Perhaps as relevant from a practical standpoint, rat studies also showed that VD11 produced lower mortality and less weight loss compared to methylprednisolone, the only currently approved immediate treatment for SCI. That comparison matters because methylprednisolone carries serious side effects including gastrointestinal ulcers, hyperglycemia, and respiratory complications, and some researchers are specifically investigating peptides as potentially safer alternatives for the acute treatment window.

VD11 is also smaller in molecular weight than related compounds, which makes it easier to synthesize and potentially easier to deliver. No human dosing data exists. No human trials have been registered or published as of mid-2026. The evidence here is entirely preclinical, and animal results in the SCI field have not always translated to humans. VD11 is worth knowing about because it represents the direction the research is moving, not because it is something currently accessible to people seeking SCI recovery options.

5. Semax: For Acute-Phase Neuroprotection

Semax is a synthetic analog of a fragment of adrenocorticotropic hormone, known as ACTH. It has been approved and in use in Russia for neuroprotective and cognitive applications for decades, and it appears in the SCI research literature in the context of the acute injury window, the critical period in the hours immediately following trauma when secondary injury cascades are actively unfolding.

Its primary mechanism in this context is neurotrophic support through the BDNF pathway. BDNF, or brain-derived neurotrophic factor, is a protein that supports neuron survival, growth, and differentiation. Think of it as one of the signals the nervous system uses to keep neurons alive when they are under stress. Semax promotes BDNF receptor activation, which in the acute phase of spinal cord injury may help preserve surviving neurons that would otherwise be lost to the secondary injury cascade. The window for this kind of intervention is narrow, typically described as the first four hours after injury.

No FDA-recognized clinical trial data exists for Semax in spinal cord injury. Its use in the acute SCI context is based on preclinical evidence and extrapolation from its broader neuroprotective profile in Russian clinical practice. In Western regulatory contexts it is a research chemical with no approved indication. Its relevance to SCI specifically in the community discussion is limited compared to BPC-157 and TB-500, which receive more attention in forums focused on the subacute and chronic recovery phases. Semax appears most in discussions of acute SCI biology and in the broader neuroprotection community, where its BDNF activity is its primary draw.

6. GHK-Cu: For Oxidative Damage in the Acute Window

GHK-Cu is a naturally occurring copper peptide found in human plasma that declines with age. It is well known in the skin and cosmetic peptide space for its tissue regeneration and anti-inflammatory properties, but a separate line of research examines its relevance to spinal cord injury, focused on its antioxidant mechanism during the acute injury phase.

The mechanism of interest in SCI is GHK-Cu's activation of the Nrf2 pathway, a cellular defense system that controls the production of antioxidant proteins. In the acute hours after spinal cord injury, oxidative stress contributes significantly to secondary injury. Two specific processes are relevant: lipid peroxidation, which is oxidative damage to the fatty membranes of neurons, and excitotoxicity, the neuron death that occurs when excessive glutamate floods synapses and overactivates them. GHK-Cu's Nrf2 activation may counter both processes, potentially limiting the spread of secondary damage in the critical window after the initial injury.

No human clinical trial data has been published for GHK-Cu in spinal cord injury as of 2026. Its SCI relevance is based on preclinical and mechanistic research. Its practical use in the SCI recovery community is limited compared to BPC-157 and TB-500. It appears in the discussion less as a recovery tool and more as an acute cytoprotective option for people thinking carefully about the acute injury biology. Its place in this guide reflects its genuine mechanistic relevance and presence in the SCI research literature, not a broad community adoption for this use.

7. MOTS-C: For Mitochondrial Rescue After Acute Injury

MOTS-C is a mitochondria-derived peptide encoded in the mitochondrial genome, discovered relatively recently and studied primarily in the context of metabolic health, aging, and exercise physiology. Its relevance to spinal cord injury comes from a specific mechanism: its ability to activate AMPK, the cellular energy sensor, described simply as a switch that tells cells to shift their energy management strategy, and to protect mitochondrial function during periods of acute metabolic crisis.

Spinal cord injury triggers rapid failure in mitochondrial energy production in neurons at and around the injury site. Neurons that survive the initial trauma but lose the ability to produce adequate energy become vulnerable to the cascade of secondary damage that follows. MOTS-C's AMPK activation may preserve mitochondrial function and neuronal survival in that acute window by restoring the cell's capacity to generate what it needs to stay alive.

No human clinical trial data has been published for MOTS-C in spinal cord injury as of 2026. Its primary research base is in metabolic and aging contexts, with the SCI application appearing in more recent mechanistic literature exploring how mitochondrial rescue might reduce secondary injury. Like GHK-Cu, MOTS-C sits in this list because of mechanistic relevance and research-community discussion rather than established community use among people managing SCI recovery. It is accessible as a research peptide, but no validated human protocol exists for this application.

How These Peptides Compare

Frequently Asked Questions

Is NVG-291 available outside of clinical trials?

As of mid-2026, NVG-291 is not commercially available and cannot be obtained through telemedicine or the research chemical market. The only access route is enrollment in an FDA-approved clinical trial. People with chronic incomplete cervical spinal cord injuries who are between one and ten years post-injury may qualify for the ongoing trials, and ClinicalTrials.gov is the most reliable place to check current enrollment status.

Are BPC-157 and TB-500 legal to buy for personal use?

BPC-157 and TB-500 are sold online as research chemicals with labeling that states they are not for human use. In the United States they are not FDA-approved for any indication, which means using them in humans is not legally sanctioned, though personal possession of research chemicals exists in a gray area that varies by jurisdiction. The more practical concern is quality: without regulatory oversight, purity and concentration in products from unregulated vendors are unverified.

Can peptides replace physical therapy for spinal cord injury recovery?

No evidence from either clinical trials or community reporting supports using peptides as a replacement for physical therapy. In the community reports where people describe meaningful functional gains alongside peptide use, they are consistently also engaged in intensive rehabilitation, gym work, and sometimes hydrotherapy. Several users explicitly describe the peptides as potentially accelerating recovery from training sessions rather than driving recovery on their own. Physical therapy, proper nutrition, sleep, and hydration remain the established foundation of SCI rehabilitation.

How long did it take to see results in the NVG-291 trial?

In the Phase Ib/IIa CONNECT SCI trial, the primary outcome was assessed at 12 weeks. One trial participant reported noticeable hand function changes beginning around week three, with continued improvement through the full treatment course. The longer-term finding, that benefits persisted one year after stopping treatment, came from blinded qualitative exit interviews after the trial concluded. These timelines are from a 10-person trial and cannot be generalized broadly, but they are the only human data available on this question.

Why are most SCI peptides still in animal studies?

Spinal cord injury research faces several obstacles that slow the path from animal models to human trials. The heterogeneity of injuries, varying by level, completeness, and time since injury, makes trial design complex and requires larger sample sizes to detect meaningful effects. The SCI population is also relatively small, which makes recruiting participants difficult. Most compounds in the preclinical literature are years away from human trials if they get there at all, which is why NVG-291's Phase III progression represents a genuine milestone for the field.

This content is for informational and educational purposes only. It does not constitute medical advice, diagnosis, or treatment recommendations. MyPeptidePal is not a medical provider. Always consult a qualified healthcare professional before starting, modifying, or stopping any health protocol, supplement regimen, or therapeutic intervention.

Sources

The information in this guide is drawn from the MyPeptidePal knowledge base, which brings together published research, clinical data, and documented real-world use of peptides for spinal cord injury in one place.